1
Patients with localized disease and poor PS are treated with radiation therapy.
2
However, the benefit of ICIs for patients with a poor PS remains unknown.
3
Guidelines should make specific recommendations for older patients or those with a poor PS.
4
Outcome for patients with NSCLC and poor PS is dismal.
5
Thus, the efficacy of immune checkpoint inhibitors (ICIs) in patients with poor PS remains unclear.
6
Literature regarding clinical and palliative care outcomes in patients with poor PS treated with anti-PD1 is lacking.
7
Conclusion: Our regimen was suitable as second-line therapy for patients with advanced platinum-resistant UC with a poor PS.
8
The suggested treatment options for patients with metastatic disease and poor PS are single-agent chemotherapy or supportive care.
9
For those patients with poor PS, expected benefits from therapy should be weighed up carefully against the anticipated toxicities.
10
Conclusions: Gefitinib may provide clinical benefits for patients with NSCLC with poor PS who were selected according to clinically favorable parameters.
11
Herein, we used data from a retrospective cohort to assess the potential clinical benefits of ICIs in NSCLC patients with poor PS.
12
Recently, the possibility of using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor therapy has been reported for poor PS patients harboring EGFR mutations.
